A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ...

LAVAL, QC, April 21, 2026 /CNW/ - In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML). With TIBSOVO(R) ...

PureTech Health plc ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced positive topline ...

The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...

SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.

LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...

Leukemia is a cancer of blood cells that affects the blood, bone marrow, and the lymphatic system. It is a form of cancer ...

New real-world data from the 1INSPIRE study shows that frontline niraparib (Zejula) maintenance is well-tolerated in patients ...

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding ...

It may be possible to identify which pre-cancerous cells will develop into a rare type of blood cancer, due to new research ...

A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the ...

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced that the first patient has been enrolled in the VITAL-CML trial, w ...